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Epithelial Na channels mediate the transport of Na across epithe-
lia in the kidney, gut, and lungs and are required for blood pressure
regulation. They are inhibited by ubiquitin protein ligases, such as
Nedd4 and Nedd4-2, with loss of this inhibition leading to hyper-
tension. Here, we report that these channels are maintained in the
active state by the G protein-coupled receptor kinase, Grk2, which
has been previously implicated in the development of essential
hypertension. We also show that Grk2 phosphorylates the C
terminus of the channel  subunit and renders the channels
insensitive to inhibition by Nedd4-2. This mechanism has not been
previously reported to regulate epithelial Na channels and pro-
vides a potential explanation for the observed association of Grk2
overactivity with hypertension. Here, we report a G protein-
coupled receptor kinase regulating a membrane protein other than
a receptor and provide a paradigm for understanding how the
interaction between membrane proteins and ubiquitin protein
ligases is controlled.
amiloride  ubiquitin protein ligases
Epithelial Na channels (ENaC) are expressed in a wide varietyof salt-scavenging epithelia, including the distal nephron, the
colon, the lungs, and the excretory ducts of salivary and sweat
glands (1). They play a critical role in the maintenance of normal
extracellular fluid volume (2), blood pressure (2), and fluid volume
in the respiratory passages (3). Increases in their activity are
associated with hypertension, as in the autosomal dominant form of
hypertension Liddle’s syndrome (4). Increased Na channel activity
has also been proposed as the cause of the dehydration of the
respiratory surfaces that occurs in cystic fibrosis (3, 5), although
alternative explanations have been proposed (6). Conversely, re-
ductions in their activity, as occurs in pseudohypoaldosteronism
type I, lead to hypotension and depletion of extracellular fluid
volume (7, 8) as well as the accumulation of an excessive volume in
the respiratory passages (9).
In epithelia, the channels are composed of the three following
homologous subunits: -ENaC, -ENaC, and -ENaC (10).
Each of the subunits of the channel has two transmembrane
domains as well as N and C termini, which are cytosolic. The
C-terminal domain of each subunit contains a so-called PY
(PPxY) motif, which can be bound by WW domains in the
ubiquitin protein ligases Nedd4 (11, 12) and Nedd4-2 (13–16).
These ubiquitin protein ligases bind the channels in response to
increases in intracellular Na (12, 17) and ubiquitinate them
(18), causing their endocytosis and destruction (18, 19). Inter-
ruption of this regulatory system, as occurs in the autosomal
dominant condition Liddle’s syndrome, which is due to mutation
or deletion of the PY motifs in the  or  subunits of the channel,
leads to increased channel activity and hypertension (4, 11, 20).
In addition to this regulation by ubiquitin protein ligases,
ENaC are also regulated by kinases. Studies in stably transfected
Madin–Darby canine kidney cells, for example, have shown that
aldosterone and insulin, both of which activate the channels,
result in the phosphorylation of the C termini of -ENaC and
-ENaC (21). In particular, the C-terminal 20 residues of the 
subunit showed increased levels of phosphorylation in response
to these hormones. Which of the three serines in this region was
phosphorylated, however, has not been determined. Further-
more, inhibition of protein phosphatase type I with low concen-
trations of okadaic acid (OA) has been found to increase the
activity of the channels (22), consistent with phosphorylation
playing an important role in their regulation.
The present studies were stimulated by the finding that the
activity of the ENaC in salivary duct cells depended on the
presence of ATP in the cytosol. We found that the requirement
for ATP was actually due to the activity of the channels
depending on a kinase. We identified this kinase to be the G
protein-coupled receptor kinase 2 (Grk2), and we showed that
it acts on S633 in the C terminus of -ENaC. The kinase
increases the activity of the channels and renders them insen-
sitive to the ubiquitin protein ligase Nedd4-2. The results
demonstrate the existence of a previously unsuspected regula-
tory mechanism in which Na channel activity and the operation
of the Na feedback regulatory system are regulated by Grk2.
They further suggest that increased Grk2 activity, which is known
to be associated with hypertension in humans and animal models
(23), may act by interrupting Na feedback regulation of the Na
channels in the distal nephron, leading to inappropriate renal
Na absorption.
Methods
Materials. Adenosine 5-(,-imido)triphosphate (AMP-PNP),
adenosine 5-(,-methylene)triphosphate (AMP-PCP), ATP,
oligomycin, 2-deoxy-D-glucose, and heparin were obtained from
Sigma. OA, protein phosphatase inhibitor 2 (PPI2), and
LY294002 were obtained from Calbiochem. L. A. Pinna (Uni-
versity of Padua, Padua, Italy) generously provided 4,5,6,7-
tetrabromobenzotriazole. Anti-Grk2 and anti-Grk3 antibodies
were obtained from Santa Cruz Biotechnology, and the anti-
Grk2 and 3 antibody was obtained from Upstate Biotechnology
(Lake Placid, NY). mC10 (MESDSEVEAI) and mC15 (CQ-
PLDTMESDSEVEAI) were synthesized by Mimotopes (Clay-
ton, Victoria, Australia). The anti-Nedd4Nedd4-2 antibody is
described in ref. 24. The GST-(WW1,WW2)Nedd4-2 construct
(1–362mNedd4-2) was generated by PCR amplification, followed
by cloning into the EcoRI site of pGEX-2TK. GST-K48R ubiquitin
(12) and GST-(WW1,WW2)Nedd4-2 were produced in Esche-
richia coli. Bovine Grk2 was produced in Sf9 cells (25, 26).
Cell Isolation. Isolated salivary duct cells were prepared by
collagenase digestion of mandibular glands from male mice (12).
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Patch-Clamp Methods. The standard bath solution contained 145
mM NaCl, 5.5 mM KCl, 1.0 mM CaCl2, 1.2 mM MgCl2, 1.2 mM
NaH2PO4, 7.5 mM NaHepes, 7.5 mM HHepes, and 10 mM
glucose (pH 7.4). After establishing the whole-cell configuration
in an isolated cell, we replaced the bath solution with a solution
containing 145 mM Na-glutamate, 5.0 mM NaCl, 1.0 mM MgCl2,
10 mM HHepes, 10 mM glucose, and 1.0 mM EGTA; the pH was
adjusted to 7.4 with NaOH. The pipettes were filled with
solutions containing N-methyl-D-glucamine-glutamate and Na-
glutamate (together, total of 150 mM), 1.0 mM MgCl2, 10 mM
HHepes, 10 mM glucose, and 5.0 mM EGTA (pH 7.2). Glucose
was omitted from solutions containing 2-deoxy-D-glucose. ATP
was omitted from solutions containing AMP-PCP or AMP-PNP.
Current–voltage relations were obtained by applying 800-ms
voltage pulses from a resting potential of 0 mV and were initially
measured 4 min after attaining the whole-cell configuration.
Steady-state currents are the average current between 700 and 800
ms after the start of the pulse. Amiloride-sensitive current was
calculated by subtracting the current after the addition to the bath
of 100 M amiloride from the current before the addition of
amiloride. Chord conductances were calculated between 80 mV
and the reversal potential of the current (compare with ref. 12).
Phosphorylation Assays. Individual peptides (50 M) or nonpep-
tide control were incubated in triplicate at 30°C for 45 min with
8 ng/l Grk2/1 l of [-32P]ATP (10 mCiml; 1 Ci  37 GBq)
in 20 mM TrisHCl, pH 7.5/2 mM EDTA/10 mM MgCl2/1 mM
DTT/100 M ATP. The final reaction volume was 25 l. The
mixture was then transferred onto 2  2-cm P-81 paper squares.
Free [-32P]ATP was removed by washing the squares five times
in 0.75% phosphoric acid (10 ml per square per wash) and one
time in acetone before drying and counting.
Statistical Methods. Data are presented as mean  SEM. Stu-
dent’s unpaired t test was used to assess statistical significance.
Results and Discussion
The present experiments stemmed from whole-cell patch-clamp
studies in freshly isolated salivary duct cells. These showed that
the activity of ENaC was reduced when the cytosol was dialyzed
with a solution designed to inhibit phosphorylation reactions by
blocking endogenous ATP production and providing an excess
of the nonhydrolyzable ATP analogue, AMP-PNP (Fig. 1A). The
reduction in channel activity was not due to a nonspecific toxic
effect of the inhibitors of ATP production, oligomycin and
2-deoxy-D-glucose, because it was not observed when we re-
placed AMP-PNP by ATP (Fig. 1 A–C). Furthermore, it could
be completely reversed by inhibition of protein phosphatase
activity with either OA, which inhibits protein phosphatases type
1, 2A, and 2B (PP1, PP2A, and PP2B), or PPI2, a selective
inhibitor of PP1 (Fig. 1 B and C). This reversal was not due to
a generalized stimulatory effect on the activity of the channels
because the inclusion of OA in the 0-Na pipette solution did not
increase the magnitude of the amiloride-sensitive Na current
above that observed with 0-Na pipette solution alone (Fig. 1D).
Finally, we found that heparin, an inhibitor of kinases such as
casein kinase 2 (CK2) that are directed against acidic motifs (27),
could reproduce the effects on channel activity of nonspecific
Fig. 1. ENaC are regulated by phosphorylation. (A) Amiloride-sensitive currents during dialysis with 0-Na solution or 0-Na solution plus 10 mM 2-deoxy-D-
glucose/5 M oligomycin plus either 5 mM AMP-PCP or 5 mM ATP. (B) Mean steady-state current-voltage relations of the amiloride-sensitive current under the
conditions in A. (C) Amiloride-sensitive conductance during dialysis with 0-Na solution or 0-Na solution plus 2-deoxy-D-glucose/oligomycin plus 5 mM AMP-PNP,
AMP-PCP, ATP, AMP-PNP plus 10 M OA, or AMP-PNP plus 1,000 unitsml PPI2. (D) Amiloride-sensitive conductance during dialysis with 0-Na solution plus 200
gml heparin  OA or 2 gml anti-Nedd4 antibody. Amiloride-sensitive current was calculated by subtracting the current after addition to the bath of 100
M amiloride from that measured before the addition of amiloride. Data are given as mean  SEM. Statistical significance was assessed by using Student’s
unpaired t test.
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blockade of phosphorylation (Fig. 1D). It could, however, be
overcome by OA (Fig. 1D), indicating that heparin acts by
inhibiting a kinase. The inhibitory action of heparin was not
mediated by Nedd4Nedd4-2 ubiquitin protein ligases because it
was not prevented by the inclusion in the pipette solution of an
antibody directed against Nedd4 and Nedd4-2 (Fig. 1D).
We then attempted to identify the site of the phosphorylation
reaction that regulates the activity of the channels. The C-terminal
10 aa of the  subunit of the ENaC (MESDSEVEAI*; mC10)
contain a conserved acidic sequence that is phosphorylated in vivo
(21) and is a target for CK2 (27). The C-terminal 10 aa of -ENaC
have also been proposed to be the target for an unknown kinase that
maintains ENaC in the active state (28). This proposal was based
on the observations that dialysis of the mC10 peptide into the
cytosol of salivary duct cells markedly reduces the activity of the
channels and that this inhibitory effect is lost if the serines in
the peptide are mutated to glycine (28). Our finding in the present
studies that the Na channels are maintained in an active state by
a kinase led us to examine whether the inhibitory effect of mC10
can be overcome by inhibiting protein phosphatase activity with OA
or PPI2. We found that it could (Fig. 2A). Hence, the inhibitory
action of the inclusion in the pipette solution ofmC10 is due to the
peptide inhibiting the kinase that maintains the channels in an open
state.
Given that the C-terminal of -ENaC is known to be phos-
phorylated by CK2 (27), we investigated whether the kinase
could be CK2. We found that, although heparin inhibits the
channels (Fig. 1D), other inhibitors of CK2, including 4,5,6,7-
tetrabromobenzotriazole (29) and LY294002 (30), failed to do so
(Fig. 2B). Having ruled out CK2, we then used PREDIKIN, a
program that uses the amino acid sequence of a kinase to predict
its target sequence (31), to screen the kinome for other candidate
kinases. This program revealed the G protein-coupled kinases,
Grk2 and Grk3, to have the appropriate target sequence.
Furthermore, these kinases are inhibited by heparin (32), and
increased activity of Grk2 has been implicated in the develop-
ment of essential hypertension (23). We then found that inclu-
sion in the pipette solution of an antibody directed against both
Grk2 and Grk3 or of an antibody directed specifically against
Grk2 inhibited the channels, whereas heat-inactivated anti-Grk2
and Grk3 antibody, as well as an antibody selective for Grk3,
were without effect (Fig. 2C). The effect of the anti-Grk2
antibody was completely reversed by inhibition of PP1 (Fig. 2C).
Finally, we used recombinant Grk2 (25, 26) to show that Grk2
phosphorylates S633 in the C terminus of -ENaC (Fig. 2D).
Binding of Nedd4 or Nedd4-2 to ENaC is mediated by the
WW domains in these ubiquitin protein ligases, which bind to
PPxY motifs (PY motifs) in the C termini of the channel
subunits (11, 15, 20, 33). Loss of this interaction due to the
deletion or mutation of the PY motif of even a single subunit
(for example, the  subunit) leads to increased activity of the
channels (20) and causes Liddle’s syndrome in humans (4).
Fig. 2. Grk2 regulates ENaC. (A) Amiloride-sensitive conductance during dialysis with 0-Na solution plus C10 peptide  the phosphatase inhibitors OA (10
M) or PPI2 (1,000 unitsml). (B) Amiloride-sensitive conductance during dialysis with 0-Na solution plus the CK2 inhibitors, 4,5,6,7-tetrabromobenzotriazole
(100 M) or LY294002 (50 M). (C) Amiloride-sensitive conductance during dialysis with 0-Na solution antibodies (2 gml) against Grk2 or Grk3. Antibody
was inactivated (inact) at 60°C for 45 min. (D) In vitro incorporation of radioactive phosphate by Grk2 into various phosphopeptides derived from the terminal
pentadecapeptide of m-ENaC (CQPLDTMESDSEVEAI). WT is unphosphorylated CQPLDTMESDSEVEAI, S631P phosphorylated at S631 [CQPLDTMES(P)DSEVEAI],
S633P at S633 [CQPLDTMESDS(P)EVEAI], and S631PS633P at both serines [CQPLDTMES(P)DS(P)EVEAI].
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Thus, we investigated whether phosphorylation of the channel
by Grk2 alters its sensitivity to ubiquitin protein ligases. We
found that the inactivation of the channels by increased
cytosolic Na can be prevented by maintaining the channel in
a phosphorylated state by inhibition of PP1 (Fig. 3A), indi-
cating that Nedd4 and Nedd4-2 only interact with the dephos-
phorylated form of the channel. Consistent with this possibility
is the finding that the inclusion of recombinant Grk2 in the
pipette solution prevented the inhibition of the channels by
increased intracellular Na (Fig. 3A) but had no impact on the
activity of the channels when we used 0-Na pipette solution
(Fig. 3A). Finally, we found that inactivation of the channels
by the inclusion in the pipette solution of recombinant
(WW1,WW2)Nedd4-2, which like native Nedd4 and Nedd4-2
causes ubiquitin-dependent inactivation of the channels (Fig.
3B), is prevented by the protein phosphatase inhibitor OA and
by the inclusion of recombinant Grk2 in the pipette solution
(Fig. 3B). Thus, the Na feedback system and the ubiquitin
protein ligases that mediate it act only on the dephosphory-
lated form of the channel. The mechanism by which phos-
phorylation of S633 of the  subunit of the ENaC prevents the
binding of Nedd4 or Nedd4-2 is unclear. It may induce a
conformational change in the C-terminal of the subunit that
precludes binding of the ubiquitin protein ligase. Alternately,
it may recruit another protein that prevents binding of the
ligase to the channel.
In this article, we have shown that Grk2, which is expressed
in renal and other epithelia (34, 35), activates ENaC and
renders them insensitive to inhibition by ubiquitin protein
ligases (Fig. 4). The ubiquitin protein ligases Nedd4 and
Nedd4-2 mediate the inhibition and endocytosis of the chan-
nels in response to increases in intracellular Na (12, 16, 17),
and the present findings suggest that the known association
between increased Grk2 activity and the development of
essential hypertension in humans (23, 36) and in spontaneously
hypertensive and Dahl salt-sensitive rats (36) may not simply
be due to defective vascular reactivity (23, 37). Increased Grk2
activity would interrupt the Na feedback inhibitory system,
leading to increased activity and surface expression of the Na
channels in the distal nephron, which in turn would lead to
hypertension. The consequences of Grk2 activation are, thus,
similar to Liddle’s syndrome in which mutations of channel 
and  subunits that prevent interaction of Nedd4-2 with the
channel lead to interruption of Na feedback and hypertension
(17). Consistent with this proposal are the findings that
hypertensive Dahl salt-sensitive rats have increased expression
of ENaC in the kidney (38) and low circulating levels of
aldosterone (38).
An increasing number of membrane transporters have been
reported to be regulated by the Nedd4 family of ubiquitin protein
ligases, including the ENaC (11), voltage-gated Na channels
(39), and the Cl channel, ClC-5 (40). Recent studies (14, 41, 42)
have also suggested that hormones that activate ENaC and
voltage-gated Na channels may do so by phosphorylating
Nedd4-2, thus rendering it unable to interact with the channels.
Here, we report a paradigm in which phosphorylation of the
channel inactivates the regulatory system. Furthermore, our
findings indicate that G protein receptor kinases, which have
been thought to target only receptors (43), may play a major role
in regulating the activity and trafficking of membrane transport
proteins.
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Fig. 3. Phosphorylation of ENaC regulates their sensitivity to ubiquitin
protein ligases. (A) The effect of OA (10 M), PPI2 (1,000 unitsml), or recom-
binant Grk2 (1 gml) on the inhibition of the amiloride-sensitive conduc-
tance produced by dialyzing the cells with 70 mM Na solution. (B) The effect
on the amiloride-sensitive conductance of dialyzing the cells with 0-Na
solution containing recombinant 1–362mNedd4-2 ((WW1,WW2)Nedd4-2,
100 gml) the 100 gml K48R mutant of ubiquitin, 10 M OA, or 1 gml
recombinant Grk2.
Fig. 4. Model summarizing the present findings. These findings indicate that
the ENaC exists in the following two states: a phosphorylated state that has
high activity and a dephosphorylated state that has low activity. The equilib-
rium between the phosphorylated and the dephosphorylated states is main-
tained by the kinase Grk2 and PP1. Inhibition of the kinase by the inclusion in
the pipette solution of nonhydrolyzable analogues of ATP, such as AMP-PNP
and AMP-PCP, or the Grk2 inhibitor, heparin, or of an excess of its substrate the
terminal decapeptide of the  subunit of the channel (C10), leads to de-
creased channel activity. Conversely, inhibition of the phosphatase with OA or
PPI2, leads to an increase in the activity of the channel. Only the dephospho-
rylated form of the channel is sensitive to inhibition by Nedd4Nedd4-2
ubiquitin protein ligases. Hence, the inhibition of the channel by increased
intracellular Na, which is mediated by these ubiquitin protein ligases, can be
overcome by maintaining the channel in the phosphorylated state.
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